Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III pembrolizumab versus placebo as adjuvant therapy after resection or local ablation for hepatocellular carcinoma
CTR20191629Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of pembrolizumab in hepatocellular carcinoma (HCC), sponsored by Merck & Co.. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20191629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191629.